About EnzymeRx - Management Team
Tony Fiorino, MD, PhD
President and Chief Executive Officer
Previously, Tony managed long-short biotechnology portfolios at Pequot Capital Management and Sands Point Partners, and before that served as a biotechnology analyst at Citigroup Asset Management, a long-only institutional money manager. Before becoming a biotechnology investor, Tony spent his first few years on Wall Street as a large-cap U.S. pharmaceuticals analyst at JP Morgan Securities. Prior to entering the world of finance, Tony trained in medicine and dermatology at the Hospital of the University of Pennsylvania after completing the M.D.-Ph.D. program at the Albert Einstein College of Medicine. He received a B.S. in Biology from the Massachusetts Institute of Technology. Tony was elected to Alpha Omega Alpha, Phi Beta Kappa and Sigma Xi and has authored over 20 publications in the medical and scientific literature. Tony is also a director of Stemline, a private biotechnology company.
John Bomalaski, MD
Chief Medical Officer
John Bomalaski is the Chief Medical Officer of EnzymeRx. In addition, he is Vice President of Medical Affairs for Polaris Pharmaceuticals, Inc and co-founded Phoenix Pharmacologics, Inc. Dr. Bomalaski earned his M.D. degree from St. Louis University. He was an intern and medical resident at Northwestern University, and then was chief medical resident at Northwestern Memorial Hospital, and went on to a rheumatology fellowship at the University of Pennsylvania. He was a faculty member at the University of Pennsylvania and Medical College of Pennsylvania, rising to full professor of medicine, before moving to industry. He is the author of over 130 publications in over 40 different journals, and is also co-author of a book on rheumatology. Dr. Bomalaski is board certified in internal medicine and rheumatology.